The Role of the Human Bocavirus (HBoV) in Respiratory Infections

Oliver Schildgen and Verena Schildgen

Introduction

The current classification of human bocaviruses is based on the latest recommendations of the International Committee for the Taxonomy of Viruses (ICTV) (https://talk.ictvonline.org/taxonomy/). The variant 1 of the human bocavirus (HBoV-1) that causes respiratory infections in primates and humans belongs to the family of Paroviridae, subfamily Parovirinae and genus *Bocaparvovirus* and was discovered originally in 2005 by Tobias Allander [1] and co-workers and represents together with the strains HBoV-3 and the gorilla bocavirus the species *Primate bocaparvovirus 1* [2].

The discovery of HBoV-1 was one among a series of virus discoveries that occurred during the first 15 years of this century. These discoveries were based on novel virus discovery systems using molecular approaches developed in order to reduce the considerable number of cases in which a clinical diagnosis of a respiratory infection could not be confirmed by the laboratory detection of a pathogen. Following the initial description of the virus, a huge number of clinical studies and case reports have been published which were supplemented by some basic research reports. In parallel, several related viruses have been newly identified, such as a swine bocavirus, a feline bocavirus and a novel canine parvovirus, of which of them share some biological features with HBoV [3, 4]. In 2016, an additional novel bocavirus variant occurring in chimpanzees was identified, which along with the gorilla virus gives rise to the assumption that a long co-evolution between primates and bocaviruses exists [5–7].

Unfortunately, HBoV research still relies on clinical studies and case reports with accompanying cell culture studies as the major source of information on HBoV.
pathophysiology, because to date no animal model has been identified. Preliminary data on the use of ferrets as a model for gene therapy with HBoV capsid-based vectors suggests that ferrets might be a possible model for future research on HBoV-host interactions and vaccinations [8].

**HBoV Biology**

The human bocavirus (HBoV) was initially discovered in clinical samples from the respiratory tract of children suffering from respiratory infections of unknown aetiologies [1]. To date, HBoV is the fourth most detected respiratory virus, but as there is still no animal model or a broadly convertible cell culture available, Koch’s modified postulates have not been experimentally fulfilled yet [9], but a case study from the group of Maria Söderlund-Venermo, Klaus Hedman and Olli Ruuskanen has shown that human-to-human transmission is most likely [10]. This report describes an intra-family infection chain that was characterized by both symptomatic and asymptomatic infections/transmissions, subsequent reactivation of the virus and hints for latency of HBoV.

Nevertheless, HBoV is the second parvovirus known so far that is capable of infecting humans with the potential to cause clinical disease. Until HBoV was discovered, the parvovirus B19 was the sole human parvovirus, which is difficult to culture in in vitro cell cultures, likely because infection strongly depends on the optimal cell cycle phase [11–20]. This latter fact hampered the development of potent and specific antivirals; tenacity studies and the development of disinfectants active against human paroviruses as surrogate pathogens with animal pathogenicity were used. The narrow parvoviral host tropism also hampered the development of cell culture systems that support the replication of human bocavirus.

The discovery of HBoV has resulted in several molecular findings that are of major interest regarding the pathophysiology of human parvovirus. Within a primary cell culture in which the human bocavirus was replicating, it was possible to identify the HBoV transcriptome including splicing variant of viral RNA [21]. This cell culture demonstrated for the first time a potential tool for the investigation of human parovirus in its natural infectious setting, enabling investigations of the molecular biology of human paroviruses in general and HBoV in particular. Unfortunately, the primary cell culture that enables HBoV growth in vitro is very expensive and requires a highly specialized laboratory. Moreover, this is an error-prone cell culture, which means the availability of this technology is limited to several laboratories worldwide, which in turn will delay further research. In search for a broadly convertible replication system, the group headed by Dr. Jianming Qiu from the University of Kansas Medical Center made a significant step forward: this group has established a plasmid-based replicon-like system that has identified additional RNA species that are transcribed during the HBoV replication cycle [22]. The system is based on plasmids that contain the complete published HBoV sequence but are flanked by ITR regions of the adeno-associated virus (AAV); the ITR regions
are terminal repeats containing palindromic sequences that form hairpin-like structures which in turn are required for the replication of paroviruses according to the so-called rolling hairpin mechanisms of replication [23]. With this first replicon system, Chen et al. have shown that HBoV types 1 and 2 express a similar RNA pattern like other paroviruses. In particular, they identified a spliced NS-1 transcript that was not recognized before and have shown that the NP-1 transcripts are expressed abundantly [22]. In this context it is worth to note that the viral NP1 protein, which is a small NS protein encoded by the middle open reading frame, is required for the expression of viral capsid proteins (VP1, VP2 and VP3), whereas the other NS proteins (NS1, NS2, NS3 and NS4) are not essential for the expression of VP proteins [24].

Although the hairpin-like structures of HBoV were not described when the first genomic analyses were performed, it has been postulated that the HBoV genome also is flanked by such structures and that HBoV replicates its genome by the rolling hairpin mechanism, although this assumption is exclusively based on phylogenetic analogous conclusion rather than on experimental evidence. In theory, the rolling hairpin replication results in progeny genomes that occur in equal amounts of both polarities, whilst packaging of viral genomes is dependent on additional factors [25–31]. For almost four decades, it is postulated that all paroviruses replicate according to this mechanism, although this replication model is solely based on experimental data obtained by the research on rodent paroviruses. The model is characterized by a terminal hairpin-dependent self-priming initiation of the viral genome replication and concatemeric replication intermediates of head-to-head or tail-to-tail replication intermediates. Based on an early publication of the postulated model in 1976 in Nature, this replication model became a dogma in the field of parovirology and was deemed to be true for all paroviruses. Interestingly it was impossible to identify both genome polarities in clinical samples containing HBoV-infected cells [32]. Thereby, NASBA analyses revealed that all HBoV strains package negative-strand genome, whilst only a minority also packages the plus strand; this observation is compatible with another replication mechanism known as rolling circle replication. In order to test the hypothesis if rolling circle replication may occur in HBoV infection and in order to decipher the unknown terminal hairpins, a couple of systematic PCR-based analyses were performed [33].

This approach has identified DNA sequences that contain head-to-tail genome fragments linked by a newly identified linker stretch that has a partial by high homology to the minute virus of canine (MVC) ITR and to the ITR of bovine parovirus. Most recently it was shown that these sequences most likely represent the missing terminal hairpin-like structures [33, 34]. Despite identifying the terminal sequences in both clinical samples and cell cultures, a lack of self-priming activity of HBoV genomes as well as the lack of intermediates typical for rolling hairpin replication has been noted. Instead the samples contained head-to-tail structures.

Additional groups have published similar observations, all questioning the dogma of parovirus replication [35–38]. It is thereby important to know that the head-to-tail episomal form of HBoV differs from formerly described circular paroviral
episomes that have been shown to consist circular-closed genome dimers of head-to-head and tail-to-tail orientation [39].

Although the role of the linker sequence and the head-to-tail junction remains unclear, these findings were surprising as they support the hypothesis that HBoV replicates differently from non-human parvoviruses by possibly initiating a rolling circle mechanisms, at least as an alternative route of replication.

Based on the newly identified sequences, the structure of the putative terminal repeats of the HBoV genome was predicted in silico [34]. In addition, the Kansas group has developed a true full-length vector clone of HBoV which can be transfected to HEK-293 cells and produced a “recombinant wild-type” human bocavirus that in turn is infectious for differentiated CuFi-8 cells [40]. CuFi-8 cells are derived from a patient with cystic fibrosis and can be grown as monolayer cultures that can be differentiated into a polarized respiratory epithelial structure by changing the culturing media. This polarized respiratory epithelial structure in turn supports HBoV replication [40]. It is worth noting that CuFi-8 cells experience a serious cytopathic effect that is able to destroy the cellular glycocalyx structures (Fig. 1) and is accompanied by a loss of cilia [41]. This novel cell culture moreover supports the hypothesis that HBoV is a serious pathogen as it induced a remarkable cytopathic effect in the polarized CuFi-8 cell line which in turn is compatible with the assumption that the clinical symptoms of an HBoV infection are caused by tissue damages related to viral replication. Thereby, this infection model harbours a surprising feature that is a further hint for an alternative replication of the human bocavirus: if the full-length HBoV plasmid containing the hairpin sequences is transfected into HEK293 cells, infectious progeny virions are produced although based on the rolling hairpin model this process should be impossible, as the free (!) hairpin sequences are believed to be essential for the replication. In contrast, replication is possible in the plasmid although they are flanked by the vector’s backbone sequence and no helper plasmids are required as known for the dependoviruses. This simple observation strongly contradicts the model of rolling hairpin replication but in turn favours other replication models known for circular DNA, as, for exam-

Fig. 1 Loss of cilia from glycocalyx of HBoV-infected cells in comparison to mock-infected cells
ple, the rolling circle replication, which in the natural infection would produce head-to-tail concatemers. However, it has to be mentioned that despite these conflicting data, the minimal essential origin of replication was identified in the right-end hairpin sequence [42]. Thereby, unlike other parvoviruses, the HBoV-NS1 protein did not specifically bind to the oriR in vitro, indicating that other viral and/or cellular components or oligomerization of NS1 is required for NS1 binding to the oriR. Of note, NP-1 and other viral nonstructural proteins (NS1–4) co-localized with the viral replication centres [42]. During the viral replication cycle, it appears that the expression of viral capsid proteins is regulated by polyadenylation mechanisms of the viral RNA transcripts [43]. It was shown that in addition to a distal polyadenylation signal named (pA)d, a further distal polyadenylation site named (pA)d2 is present in the right-end hairpin sequence, which does not contain the typical hexanucleotide polyadenylation motif. Moreover, the viral replication is strongly dependent on a newly identified small non-coding RNA named BocaSR within the 3′ non-coding region (nt 5199–5338) [44]. This RNA is transcribed by the RNA polymerase III from an intragenic promotor at amounts similar to the RNAs of the nonstructural genes. BocaSR accumulates in the replication centres within the nucleus and is suspected to directly influence the viral DNA replication.

Furthermore, clinical observations give rise to the hypothesis that the HBoV replication can be triggered or influenced by human herpesviruses such as HHV-6, CMV and herpes simplex virus. In this context it is noteworthy that herpesviruses, especially HSV, are capable of initiating a rolling circle replication mechanism of replication in trans as shown for SV40, which has a circular double-stranded genome [45].

Thereby herpesviruses may either act as a trigger that arrests the host cell at transition from G1- to S-phase of the cell cycle, or they could directly interact with the HBoV DNA supporting the replication by the herpesviral replication enzymes. The latter appears likely, as head-to-tail intermediates are a feature of the rolling circle replication that may be initiated by a couple of viruses including the human herpesviruses type 1 and type 6 [45–52]. These viruses (e.g. the adeno-associated virus, AAV) in turn are able to act as helper viruses for the parvoviral subclass dependoviruses that require those helper viruses for their replication [48–52]. Recently, a clinical case was observed in which the HBoV infection appeared to depend on a co-infection and co-replication of human herpesvirus type 6. In this case the HBoV infection persisted because of an immune disease but was terminated by antiviral therapy with cidofovir which is directed against HHV6 [53]. This was the key observation leading to the assumption that HBoV is either sensitive to cidofovir or that a possible rolling circle HBoV replication is triggered by HHV6, which in turn would explain the high frequency of co-infections observed in case of HBoV [52, 54, 55].

In 2011, two severe cases of respiratory failure in adults associated with HBoV infection and herpesvirus co-infection, with a history of lung fibrosis likely related to the presence of chronic HBoV infection [56], strongly suggest that the head-to-tail structures could have been episomal reservoirs enabling the virus’ persistence as postulated by Kapoor and co-workers [35]. It may be speculated as to whether the persistence of HBoV episomes in the lung of the patients is analogous to a HBV
infection, in which episomal cccDNA persists in the infected cell until the cell is targeted by the immune response or subjected to apoptosis and in which this chronic state frequently produces a mild inflammation that is subclinical but could induce fibrosis over time. The persistence of HBoV episomes in the lung could have led to mild chronic inflammation eventually resulting in fibrosis of the lung, which would not be easily compensated as in the liver. In the context of a putative chronic HBoV infection or a persistence of HBoV at a subclinical level, it thus appears possible that HBoV could directly or indirectly, by interactions with the immune system, contribute to chronic lung disease such as idiopathic lung fibrosis.

Another, recently detected novel feature of HBoV is the expression of more non-structural proteins that concluded from our previous knowledge on parvovirus replication studies. Shen et al. have shown that besides NS1 three novel proteins named NS2, NS3 and NS4 are expressed during the viral replication, of which NS2 is believed to have a crucial role during the viral life cycle [57].

Moreover it is important to mention that the HBoV replication cycle is independent of the cell cycle phase. As early as in 2010, it was shown in A549 cells that the expression of HBoV-1 proteins, unlike the parvovirus B19 infection, does not induce cell cycle arrest and apoptosis [22]. In contrast, two recent studies have shown that the DNA damage repair system is involved in HBoV-1 replication [58, 59]. Thereby the hallmarks of the DDR response, the phosphorylation of H2AX and RPA32, are activated accompanied by the activation of all three PI3KKs. In addition, the polymerases Pol-η and Pol-κ, both being part of the DNA repair system, are recruited to the viral replication sites, thus providing additional evidence that parvovirus DNA replication has to occur in cell cycle-arrested cells.

**Epidemiology**

Like all respiratory pathogens (except SARS and MERS coronavirus) causing respiratory infections, HBoV-1 is distributed worldwide and has been detected in patients from several regions of each continent [60–112]. However, unlike most other viruses that are known to peak seasonally in autumn and winter, HBoV infection peaks do not seem to be restricted to these seasons.

Although the route of transmission was not yet systematically investigated, it is widely accepted that the transmission of HBoV most likely occurs by smear or droplet infections or aerosols and nasal or oral uptake as described for the majority of “common cold viruses.” The transmission route passes through airway excretions but could also be via the gastrointestinal route, as HBoV is shedded also by stool (Figs. 2 and 3).

The HBoV seroprevalence is high and reached 95% and more in children up to the age of 5 years [113, 114]. This seroprevalence remains high in most adults [76, 82] but decreases from 96% to 59% in European adults if antibodies against HBoV strains two to four were depleted. Thus in 41% of patients, no long-term immunity could be generated, supporting the assumption that the virus is able to persist and
could also reinfect elderly patients [115]. Surprisingly, HBoV-1 DNA can also be detected in blood and blood products from healthy Chinese blood donors with a lower seropositivity compared to the above-mentioned cohorts [116].

In recent months a few studies have been published that demonstrated that human bocaviruses are also stable in the environment. As an example, Iaconelli et al. have shown the frequent detection of HBoV in urban sewages, an observation confirmed by a study from Egypt [117].

**Clinical Features**

HBoV-1 respiratory infection is clinically indistinguishable from other respiratory infections and can only be diagnosed using molecular assays. The spectrum of HBoV infections ranges from asymptomatic [67, 118, 119] to mild upper respiratory infections [67, 120–122] up to serious and life-threatening lower respiratory tract infections [70, 109, 123–133] in all age groups [70, 71, 109, 119, 123–136]. The immune response against HBoV starts with an IgM response and is followed by...
Fig. 3  Schematic overview of the HBoV life cycle. (1) Entry through the nasopharyngeal space, (2) infection of the lung, (3) and (4) swallowing of the expectorated infectious secretion, and (5) infection of the gastrointestinal tract. Additionally, the virus spreads via the bloodstream and causes classical viremia (not indicated)
the formation of IgG [113, 114], but no lifelong immunity is generated in at least 40% of patients due to the original antigenic sin [i.e. Hoskins effect] [76, 82, 137].

The general HBoV-1 infections appear to start in the upper airways; in 2014 Proenca-Modena and co-workers demonstrated that hypertrophic adenoid is a major infection site with 25.3% of tested tissues positive for viral RNA and DNA, followed by nasopharyngeal secretions (10.5%), tonsils (7.2%) and peripheral blood (1.5%) [138]. Thereby it is worth to note that tonsils are suspected to be a major site of persistence as hypothesized by Clement and colleagues [139]. Subsequently the virus most likely initiates a downstream infection caused by swallowing of virus-containing secretions, which then enter the gastrointestinal tract where active viral replication occurs and is accompanied by a true viremia. Persistence of HBoV in the respiratory tract has been confirmed by a novel pyrosequencing approach by Wagner and co-workers, who observed primary infections and recurrence in a large cohort of paediatric patients [140].

HBoV-1 is able to infect the central nervous system and induces clinical symptoms of encephalitis or necrotizing encephalopathies [96, 98, 141]. HBoV-1 has been identified as a putative cause of idiopathic lung fibrosis [56] supported by the fact that a set of profibrotic cytokines were upregulated during HBoV infection in adults and their HBoV-dependent upregulation was confirmed in cell culture [142], whereas HBoV does not induce a clear Th1 or Th2 response [143]. The HBoV-dependent regulated cytokines furthermore include a subset of cytokines which are known to be involved in several cancer-associated pathways, supporting the hypothesis that HBoV may be associated with chronic diseases or even cancerogenesis [144–146]. Although this hypothesis requires further prospective studies, HBoV DNA was detected in lung and colorectal tumours. Detection of HBoV DNA, eventually associated with persistence, has been described in addition to detection in normal lung tissue [119] and in lung and colorectal tumours [146, 147]. HBoV-1 has been detected in other tissues such as tonsils [35, 139, 148, 149] and myocardium and may affect additional tissues that have not yet been tested for HBoV positivity.

Lung fibrosis, especially idiopathic lung fibrosis (IPF), is characterized by a Th2-type dominated immune response in the affected tissue (reviewed by [150–152]). The Th2 response in the lung is accompanied by increased expression levels of IL-4, IL-5, IL-10 and IL-13 and is followed by increased levels of CCL17 (TARC), CCL5 (RANTES) and others. Moreover, fibrosis is related to expression of TNF and IL-8; it is worth noting that the neutralization of TARC leads to a reduction of fibrosis in the animal model [151, 153]. In addition, an elevation of the TARC/IP-10 ratio is also characteristic for fibrosis and was previously discussed as a marker for IPF [154].

Moreover, a unique case has been described in which the infection/reactivation of HBoV occurred between two episodes of BAL sampling; the fibrosis-associated cytokines were expressed in association with the HBoV infection but not before, supporting the previously mentioned data. This data leads to the conclusion that HBoV colonization/chronic infection may be at least one trigger that could stimulate airway remodelling. However, it could be argued that not only the resident airway epithelial cells are involved in the in vivo immune response, but also additional patient-specific factors will contribute to altered profibrotic cytokine profiles. In
order to address this problem, experiments in an air-liquid interface culture of human airway epithelial cells were performed. These experiments confirmed that profibrotic cytokines were expressed by the infected cell cultures but were minimally or not at all expressed in mock-infected cells; the identified cytokines belong to the initial immune response following HBoV infection [123].

According to the literature, the two HBoV proteins VP2 and NP1 seem to influence the regulation of the interferon-beta pathway, but the data appear to be controversial as VP2 upregulates the pathway [155], whilst NP1 inhibits the IFN-beta production when overexpressed [156]. In addition, in an experimental setting with overexpression conditions, it has been shown that HBoV NS1 and Ns1–70 proteins inhibit the TNF-α-mediated activation of NF-κB by targeting p65 [157].

Moreover, based on clinical observations of a longitudinal study, Martin and colleagues concluded that HBoV infections could possibly be divided into two distinct clinical subgroups, one with a short viremic phase and short viral shedding, most likely being the primary infection, and a second group with long-term shedding; the second group is likely to be co-infections with other pathogens or a reactivation of a persistent HBoV infection [158].

Coinfections and Persistence

Simultaneously with the discovery of HBoV in 2005, multiplexing PCR methods started to become an accepted diagnostic tool, and consequently detection of multiple infections, especially in respiratory tract diseases, has become a common phenomenon [67, 159–163]. Nowadays, multiple infections with up to six pathogens being simultaneously present in a single respiratory sample are frequent [67, 159–164] and may mislead some researcher to claim that the human bocavirus, also occurring in asymptomatic patients, is a harmless bystander rather than a pathogen [165, 166]. This hypothesis seems to be supported by the fact that a formal fulfilment of Koch’s modified postulates was not yet possible for HBoV [167], as no animal model exists to date and volunteer transmission trials cannot be recommend based on our current knowledge of this virus [145].

In contrast, although there is a cohort of asymptomatic carriers [67, 119, 159, 166, 168, 169], several studies have shown that HBoV induces clinical respiratory symptoms [64, 91, 126, 127, 159, 170–176]. The asymptomatic viral shedding is meanwhile believed to originate from long-term shedding after an acute infection or from persistent viruses [34, 35, 95, 137, 177–180]. This has most recently been confirmed by a long-term prospective cohort study [67, 181]. Thereby it was shown that the rate of asymptomatic HBoV infections is similar to the rate of rhinovirus infections and no one would doubt that rhinoviruses are true pathogens [67]. Finally, HBoV is known to induce serious cytopathic effects in infected cell cultures, which is a typical feature of a pathogen [21, 40, 57, 177].
Diagnostics

In addition to several published home-brew PCRs and real-time PCRs (reviewed by [9]), numerous commercial assays, such as the Luminex RVP assay [119, 182], the Idaho FilmArray [164, 182] or the RespiFinder assay [119], have been developed and released to the market enabling the detection of HBoV from clinical samples. However, multiplexing solely allows detection of the viral DNA in a respiratory sample without providing the essential information as to whether an active replicative infection underlies the currently clinical episode requiring laboratory testing [67]. As HBoV can be shedded for longer than 3 months after the acute symptomatic phase [67], a proper diagnostics of human bocavirus requires the proof of active replication, which can be done either by detection of a viremia in the peripheral blood [91, 107, 115, 137, 183–187] or by detection of spliced viral RNA transcripts that were shown to be present exclusively during the active phase of the replication [188]. Recently, a novel rapid antigen test was developed which could be a major advance in HBoV diagnostics [189]. Further progress in this direction can be expected from novel approaches to test for human antibodies and bocviral antigens from all four subtypes based on yeast-derived virus-like particles [190].

Advanced Molecular Techniques in HBoV Research and Diagnostics

The discovery of HBoV has become possible due to the usage of a novel virus discovery strategy used by Allander and colleagues in 2005 [1]. These authors used a strategy of a virus screening library combined with a 96-well format high-throughput sequencing approach based on rolling circle amplification and sequencing. This technique was used subsequently also by other labs and has become a simple but work-intensive strategy to identify novel viruses and virus variants.

In addition, with the isolation and propagation of HBoV in three-dimensional air-liquid interface cell cultures, another novel method has set standards for the research on respiratory viruses in general and human bocavirus in particular [21]. This technique has meanwhile been refined, and several models are available [8, 40, 59, 177].

Summary and Perspective

There is an increasing body of evidence showing that the human bocavirus is a serious pathogen that is associated with acute respiratory infections, sometimes with life-threatening complications. In addition, there is evidence that the human bocavirus could contribute to long-term disease of the airways resulting in lung carcinoma
or lung fibrosis. It is therefore crucial to analyse the long-term effects of HBoV infections in order to identify the mechanisms of HBoV persistence as well as for determining host factors for asymptomatic infections and to test the hypothesis that HBoV could trigger the development of lung cancer and fibrosis. Novel studies have identified the antigenic epitopes on the viral surface and may enable the development of potent vaccines or antibody-based therapies [191].

In any cases, the proper diagnostics of HBoV require additional attention as does the need for HBoV to be evaluated in terms of its interaction with other respiratory viruses that may simultaneously be detected during clinical episodes.

References

1. Allander T, Tammi MT, Eriksson M, Bjerkner A, Tiveljung-Lindell A, Andersson B. Cloning of a human parvovirus by molecular screening of respiratory tract samples. Proc Natl Acad Sci U S A. 2005;102(36):12891–6.
2. Cotmore SF, Agbandje-McKenna M, Chiorini JA, Mukha DV, Pintel DJ, Qiu J, et al. The family Parvoviridae. Arch Virol. 2014;159(5):1239–47.
3. Cheng WX, Li JS, Huang CP, Yao DP, Liu N, Cui SX, et al. Identification and nearly full-length genome characterization of novel porcine bocaviruses. PLoS One. 2010;5(10):e13583.
4. Lau SK, Woo PC, Yeung HC, Teng JL, Wu Y, Bai R, et al. Identification and characterization of bocaviruses in cats and dogs revealed a novel feline bocavirus and a novel genetic group of canine bocavirus. J Gen Virol. 2012.
5. Brozova K, Hrazdilova K, Slaninkova E, Modry D, Cerny J, Celer V. Genetic and phylogenetic characterization of novel bocaparvovirus infecting chimpanzee. Infect Genet Evol. 2016;37:231–6.
6. Kapoor A, Mehta N, Esper F, Poljsak-Prijatelj M, Quan PL, Qaisar N, et al. Identification and characterization of a new bocavirus species in gorillas. PLoS One. 2010;5(7):e11948.
7. Sharp CP, LeBreton M, Kantola K, Nana A, Diffé Jlle D, Djoko CF, et al. Widespread infection with homologues of human parvoviruses B19, PARV4, and human bocavirus of chimpanzees and gorillas in the wild. J Virol. 2010;84(19):10289–96.
8. Yan Z, Feng Z, Sun X, Zhang Y, Zou W, Wang Z, et al. Human Bocavirus Type-1 capsid facilitates the transduction of ferret airways by Adeno-associated virus genomes. Hum Gene Ther. 2017:28:612.
9. Schildgen O, Muller A, Allander T, Mackay IM, Volz S, Kupfer B, et al. Human bocavirus: passenger or pathogen in acute respiratory tract infections? Clin Microbiol Rev. 2008;21(2):291–304.
10. Jula A, Waris M, Kantola K, Peltola V, Soderlund-Venermo M, Hedman K, et al. Primary and secondary human bocavirus 1 infections in a family, Finland. Emerg Infect Dis. 2013;19(8):1328–31.
11. Morita E, Sugamura K. Human parvovirus B19-induced cell cycle arrest and apoptosis. Springer Semin Immunopathol. 2002;24(2):187–99.
12. Morita E, Tada K, Chisaka H, Asao H, Sato H, Yaegashi N, et al. Human parvovirus B19 induces cell cycle arrest at G(2) phase with accumulation of mitotic cyclins. J Virol. 2001;75(16):7555–63.
13. Bashir T, Rommelare J, Cziepluch C. In vivo accumulation of cyclin A and cellular replication factors in autonomous parvovirus minute virus of mice-associated replication bodies. J Virol. 2001;75(9):4394–8.
14. Bashir T, Horlein R, Rommelaere J, Willwand K. Cyclin A activates the DNA polymerase delta-dependent elongation machinery in vitro: A parvovirus DNA replication model. Proc Natl Acad Sci U S A. 2000;97(10):5522–7.

15. Op De Beeck A, Caillet-Fauquet P. The NS1 protein of the autonomous parvovirus minute virus of mice blocks cellular DNA replication: a consequence of lesions to the chromatin? J Virol. 1997;71(7):5323–9.

16. Oleksiewicz MB, Alexandersen S. S-phase-dependent cell cycle disturbances caused by Aleutian mink disease parvovirus. J Virol. 1997;71(2):1386–96.

17. Op De Beeck A, Anouja F, Mousset S, Rommelaere J, Caillet-Fauquet P. The nonstructural proteins of the autonomous parvovirus minute virus of mice interfere with the cell cycle, inducing accumulation in G2. Cell Growth Differ. 1995;6(7):781–7.

18. Bantel-Schaal U, Stohr M. Influence of adeno-associated virus on adherence and growth properties of normal cells. J Virol. 1992;66(2):773–9.

19. Metcalf JB, Bates RC, Lederman M. Interaction of virally coded protein and a cell cycle-regulated cellular protein with the bovine parvovirus left terminus ori. J Virol. 1990;64(11):5485–90.

20. Siegl G. Molecular biology and pathogenicity of human and animal paroviruses. Behring Inst Mitt. 1990;85:6–13.

21. Dijkman R, Koekkoek SM, Molenkamp R, Schildgen O, van der Hoek L. Human bocavirus can be cultured in differentiated human airway epithelial cells. J Virol. 2009;83(15):7739–48.

22. Chen AY, Cheng F, Lou S, Luo Y, Liu Z, Delwart E, et al. Characterization of the gene expression profile of human bocavirus. Virology. 2010;403(2):145–54.

23. Tattersall P, Ward DC. Rolling hairpin model for replication of parvovirus and linear chromosomal DNA. Nature. 1976;263(5573):106–9.

24. Zou W, Cheng F, Shen W, Engelhardt JF, Yan Z, Qiu J. Nonstructural protein NP1 of human Bocavirus 1 plays a critical role in the expression of viral capsid proteins. J Virol. 2016;90(9):4658–69.

25. Cotmore SF, Gottlieb RL, Tattersall P. Replication initiator protein NS1 of the parvovirus minute virus of mice binds to modular divergent sites distributed throughout duplex viral DNA. J Virol. 2007;81(23):13015–27.

26. Cotmore SF, Tattersall P. Encapsulation of minute virus of mice DNA: aspects of the translocation mechanism revealed by the structure of partially packaged genomes. Virology. 2005;336(1):100–12.

27. Cotmore SF, Tattersall P. Genome packaging sense is controlled by the efficiency of the nick site in the right-end replication origin of paroviruses minute virus of mice and LuIII. J Virol. 2005;79(4):2287–300.

28. Corsini J, Cotmore SF, Tattersall P, Winocour E. The left-end and right-end origins of minute virus of mice DNA differ in their capacity to direct episomal amplification and integration in vivo. Virology. 2001;288(1):154–63.

29. Cotmore SF, Tattersall P. An asymmetric nucleotide in the parvoviral 3′ hairpin directs segregation of a single active origin of DNA replication. EMBO J. 1994;13(17):4145–52.

30. Cotmore SF, Nuesch JP, Tattersall P. Asymmetric resolution of a parvovirus palindrome in vitro. J Virol. 1993;67(3):1579–89.

31. Cotmore SF, Nuesch JP, Tattersall P. In vitro excision and replication of 5′ telomeres of minute virus of mice DNA from cloned palindromic concatemer junctions. Virology. 1992;190(1):365–77.

32. Bohmer A, Schildgen V, Lusebrink J, Ziegler S, Tillmann RL, Kleines M, et al. Novel application for isothermal nucleic acid sequence-based amplification (NASBA). J Virol Methods. 2009;158(1–2):199–201.

33. Lusebrink J, Schildgen V, Tillmann RL, Wittljen F, Bohmer A, Muller A, et al. Detection of head-to-tail DNA sequences of human bocavirus in clinical samples. PLoS One. 2011;6(5):e19457.
34. Schildgen O, Qiu J, Soderlund-Venermo M. Genomic features of the human bocaviruses. Future Virol. 2012;7(1):31–9.
35. Kapoor A, Hornig M, Asokan A, Williams B, Henriquez JA, Lipkin WI. Bocavirus episome in infected human tissue contains non-identical termini. PLoS One. 2011;6(6):e21362.
36. Li L, Pesavento PA, Leutenegger CM, Estrada M, Coffey LL, Naccache SN, et al. A novel bocavirus in canine liver. Virol J. 2013;10:54.
37. Zhao H, Zhao L, Sun Y, Qian Y, Liu L, Jia L, et al. Detection of a bocavirus circular genome in fecal specimens from children with acute diarrhea in Beijing, China. PLoS One. 2012;7(11):e48980.
38. Yang WZ, Huang CP, Duan ZJ. Identification and characterization of porcine bocavirus episomes. Bing Du Xue Bao. 2012;28(4):418–23.
39. Schnepp BC, Clark KR, Klemanski DL, Pacak CA, Johnson PR. Genetic fate of recombinant adeno-associated virus vector genomes in muscle. J Virol. 2003;77(6):3495–504.
40. Huang Q, Deng X, Yan Z, Cheng F, Luo Y, Shen W, et al. Establishment of a reverse genetics system for studying human bocavirus in human airway epithelia. PLoS Pathog. 2012;8(8):e1002899.
41. Helling A-E, Pieper M, Naumova E, Arnold WH, Schildgen O, Schildgen V. Morphological evaluation of CuFi-1, CuFi-5 and CuFi-8 cell cultures before and after infection with Human Boca Virus (HBoV). Annual Meeting of the Microbiology Society; Edinburgh 2017
42. Shen W, Deng X, Zou W, Engelhardt JF, Yan Z, Qiu J. Analysis of cis and trans requirements for DNA replication at the right-end hairpin of the human Bocavirus 1 genome. J Virol. 2016;90(17):7761–77.
43. Hao S, Zhang J, Chen Z, Xu H, Wang H, Guan W. Alternative Polyadenylation of human Bocavirus at its 3′ end is regulated by multiple elements and affects capsid expression. J Virol. 2017;91(3):e00206.
44. Wang Z, Shen W, Cheng F, Deng X, Engelhardt JF, Yan Z, et al. Parvovirus expresses a small noncoding RNA that plays an essential role in virus replication. J Virol. 2017;91:e02375.
45. Gerspach R, Matz B. Herpes simplex virus-induced "rolling circle" amplification of SV40 DNA sequences in a transformed hamster cell line correlates with tandem integration of the SV40 genome. Virology. 1989;173(2):723–7.
46. Gerspach R, Matz B. Herpes simplex virus-directed overreplication of chromosomal DNA physically linked to the simian virus 40 integration site of a transformed hamster cell line. Virology. 1988;165(2):282–5.
47. Schildgen O, Graper S, Blumel J, Matz B. Genome replication and progeny virion production of herpes simplex virus type 1 mutants with temperature-sensitive lesions in the origin-binding protein. J Virol. 2005;79(11):7273–8.
48. Alazard-Dany N, Nicolas A, Ploquin A, Strasser R, Greco A, Epstein AL, et al. Definition of herpes simplex virus type 1 helper activities for adenovirus-early replication events. PLoS Pathog. 2009;5(3):e1000340.
49. Johansson S, Buchmayer S, Harlid S, Iliadou A, Sjoholm M, Grillner L, et al. Infection with parvovirus B19 and herpes viruses in early pregnancy and risk of second trimester miscarriage or very preterm birth. Reprod Toxicol. 2008;26(3–4):298–302.
50. Rollin R, Alvarez-Lafuente R, Marco F, Jover JA, Hernandez-Garcia C, Rodriguez-Navas C, et al. Human parvovirus B19, varicella zoster virus, and human herpesvirus-6 in mesenchymal stem cells of patients with osteoarthritis: analysis with quantitative real-time polymerase chain reaction. Osteoarthr Cartil. 2007;15(4):475–8.
51. Rohayem J, Dinger J, Fischer R, Klingel K, Kandolf R, Rethwilm A. Fatal myocarditis associated with acute parvovirus B19 and human herpesvirus 6 coinfection. J Clin Microbiol. 2001;39(12):4585–7.
52. Thomson BJ, Weindler FW, Gray D, Schwaab V, Heilbronn R. Human herpesvirus 6 (HHV-6) is a helper virus for adenovirus-associated virus type 2 (AAV-2) and the AAV-2 rep gene homologue in HHV-6 can mediate AAV-2 DNA replication and regulate gene expression. Virology. 1994;204(1):304–11.
The Role of the Human Bocavirus (HBoV) in Respiratory Infections

53. Streiter M, Malecki M, Prokop A, Schildgen V, Lusebrink J, Guggemos A, et al. Does human bocavirus infection depend on helper viruses? A challenging case report. Virol J. 2011;8:417.

54. Asano Y, Yoshikawa T. Human herpesvirus-6 and parvovirus B19 infections in children. Curr Opin Pediatr. 1993;5(1):14–20.

55. Bauer HJ, Monreal G. Herpesviruses provide helper functions for avian adeno-associated parvovirus. J Gen Virol. 1986;67(Pt 1):181–5.

56. Windisch W, Schildgen V, Malecki M, Lenz J, Brockmann M, Karagiannidis C, et al. Detection of HBoV DNA in idiopathic lung fibrosis, cologne. Germany J Clin Virol. 2013;58(1):325–7.

57. Shen W, Deng X, Zou W, Cheng F, Engelhardt JF, Yan Z, et al. Identification and functional analysis of novel non-structural proteins of human Bocavirus 1. J Virol. 2015;89:10097.

58. Deng X, Xu P, Zou W, Shen W, Peng J, Liu K, et al. DNA damage signaling is required for replication of human Bocavirus 1 DNA in dividing HEK293 cells. J Virol. 2017;91(1):e01831.

59. Deng X, Yan Z, Cheng F, Engelhardt JF, Qiu J. Replication of an autonomous human parvovirus in non-dividing human airway epithelial cells. PLoS Pathog. 2016;12(1):e1005399.

60. Akinloye OM, Ronkko E, Savolainen-Kopra C, Ziegler T, Iwalokun BA, Deji-Agboola MA, et al. Specific viruses detected in Nigerian children in association with acute respiratory disease. J Trop Med. 2011;2011:690286.

61. Albuquerque MC, Pena GP, Varella RB, Gallucci G, Erdman D, Santos N. Novel respiratory virus infections in children. Brazil Emerg Infect Dis. 2009;15(5):806–8.

62. Al-Rousan HO, Meqdam MM, Alkhateeb A, Al-Shorman A, Qaisy LM, Al-Moqbel MS. Human bocavirus in Jordan: prevalence and clinical symptoms in hospitalised paediatric patients and molecular virus characterisation. Singap Med J. 2011;52(5):365–9.

63. Bastien N, Brandt K, Dust K, Ward D, Li Y. Human Bocavirus infection. Canada Emerg Infect Dis. 2006;12(5):848–50.

64. Bharaj P, Sullender WM, Kabra SK, Broor S. Human bocavirus infection in children with acute respiratory tract infection in India. J Med Virol. 2010;82(5):812–6.

65. Binns MJ, Cheng AC, Smith-Vaughan H, Sloots T, Nissen M, Whiley D, et al. Viral-bacterial co-infection in Australian indigenous children with acute otitis media. BMC Infect Dis. 2011;11:161.

66. Bubshait DK, Albualhi WH, Yousef AA, Obeid OE, Alkharsah KR, Hassan MI, et al. Clinical description of human bocavirus viremia in children with LRTI, Eastern Province. Saudi Arabia Ann Thorac Med. 2010;5(2):146–9.

67. Byington CL, Ampofo K, Stackmann C, Adler FR, Herbener A, Miller T, et al. Community surveillance of respiratory viruses among families in the Utah better identification of germs- longitudinal viral epidemiology (BIG-LoVE) study. Clin Infect Dis. 2015;61:1217.

68. Carrol ED, Mankhambo LA, Guiver M, Banda DL, Denis B, Dove W, et al. PCR improves diagnostic yield from lung aspiration in Malawian children with radiologically confirmed pneumonia. PLoS One. 2011;6(6):e21042.

69. Chieochansin T, Samransamruajkit R, Chutinimitkul S, Payunporn S, Hiranras T, Theamboonlers A, et al. Human bocavirus (HBoV) in Thailand: clinical manifestations in a hospitalized pediatric patient and molecular virus characterization. J Infect. 2008;56(2):137–42.

70. Choi EH, Lee HJ, Kim SJ, Eun BW, Kim NH, Lee JA, et al. The association of newly identified respiratory viruses with lower respiratory tract infections in Korean children, 2000-2005. Clin Infect Dis. 2006;43(5):585–92.

71. Chow BD, Huang YT, Esper FP. Evidence of human bocavirus circulating in children and adults, Cleveland. Ohio J Clin Virol. 2008;43(3):302–6.

72. Chung JY, Han TH, Kim CK, Kim SW. Bocavirus infection in hospitalized children. South Korea Emerg Infect Dis. 2006;12(8):1254–6.

73. De Vos N, Vankeerberghen A, Vaeyens F, Van Vaerenbergh K, Boel A, De Beenhouwer H. Simultaneous detection of human bocavirus and adenovirus by multiplex real-time PCR in a Belgian paediatric population. Eur J Clin Microbiol Infect Dis. 2009;28(11):1305–10.
74. Dina J, Vabret A, Gouarin S, Petitjean J, Lecoq J, Brouard J, et al. Detection of human bocavirus in hospitalised children. J Paediatr Child Health. 2009;45(3):149–53.
75. Do AH, van Doorn HR, Nghiem MN, Bryant JE, Hoang TH, Do QH, et al. Viral etiologies of acute respiratory infections among hospitalised Vietnamese children in ho chi Minh City, 2004-2008. PLoS One. 2011;6(3):e18176.
76. Endo R, Ishiguro N, Kikuta H, Teramoto S, Shirkooohi R, Ma X, et al. Seroepidemiology of human bocavirus in Hokkaido prefecture. Japan J Clin Microbiol. 2007;45(10):3218–23.
77. Esposito S, Bosis S, Nieters HG, Tremolati E, Sabatini C, Porta A, et al. Impact of human bocavirus on children and their families. J Clin Microbiol. 2008;46(4):1337–42.
78. Essa S, Owayed A, Altawalah H, Khaddah M, Behbehani N, Al-Nakib W. The prevalence of human Bocavirus, human coronavirus-NL63, human Metapneumovirus, human Polyomavirus KI and WU in respiratory tract infections in Kuwait. Med Princ Pract. 2015;24:382–7.
79. Fabbiani M, Terrosi C, Martorelli B, Valentini M, Bernini L, Cellesi C, et al. Seroepidemiology and clinical study of viral respiratory tract infections in children from Italy. J Med Virol. 2009;81(4):750–6.
80. Fouloungne V, Olejnik Y, Perez V, Elaerts S, Rodiere M, Segondy M. Human bocavirus in French children. Emerg Infect Dis. 2006;12(8):1251–3.
81. Furuse Y, Suzuki A, Kishi M, Galang HO, Lupisan SP, Olveda RM, et al. Detection of novel respiratory viruses from influenza-like illness in the Philippines. J Med Virol. 2010;82(6):1071–4.
82. Guido M, Zizza A, Bredl S, Lindner J, De Donno A, Quattrochi M, et al. Seroepidemiology of human bocavirus in Apulia. Italy Clin Microbiol Infect. 2012;18(4):E74–6.
83. Heydari H, Mamishi S, Khotaei GT, Moradi S. Fatal type 7 adenovirus associated with human bocavirus infection in a healthy child. J Med Virol. 2011;83(10):1762–3.
84. Hindiyeh MY, Keller N, Mandelboim M, Ram D, Rubinov J, Regev L, et al. High rate of human bocavirus and adenovirus coinfection in hospitalized Israeli children. J Clin Microbiol. 2008;46(1):334–7.
85. Hustedt JW, Christie C, Hustedt MM, Esposito D, Vazquez M. Seroepidemiology of human bocavirus infection in Jamaica. PLoS One. 2012;7(5):e38206.
86. Ip PM, Nelson EA, Cheuk ES, Leung E, Sung R, Chan PK. Pediatric hospitalization of acute respiratory tract infections with human Bovavirus in Hong Kong. J Clin Virol. 2008;42(1):72–4.
87. Jacques J, Moret H, Renois F, Leveque N, Motte J, Andreoletti L. Human Bovavirus quantitative DNA detection in French children hospitalized for acute bronchiolitis. J Clin Virol. 2008;43(2):142–7.
88. Kaplan NM, Dow W, Abu-Zeid AF, Shamoon HE, Abd-Eldayem SA, Hart CA. Human bocavirus infection among children. Jordan Emerg Infect Dis. 2006;12(9):1418–20.
89. Kesebir D, Vazquez M, Weibel C, Shapiro ED, Ferguson D, Landry ML, et al. Human bocavirus infection in young children in the United States: molecular epidemiological profile and clinical characteristics of a newly emerging respiratory virus. J Infect Dis. 2006;194(9):1276–82.
90. Klinkenberg D, Blohm M, Hoehne M, Mas Marques A, Malecki M, Schildgen V, et al. Risk of rotavirus vaccination for children with SCID. Pediatr Infect Dis J. 2015;34(1):114–5.
91. Korner RW, Soderlund-Venermo M, van Koningsbruggen-Rietschel S, Kaiser R, Malecki M, Schildgen O. Severe human bocavirus infection. Germany Emerg Infect Dis. 2011;17(12):2303–5.
92. Krakau M, Brockmann M, Titius B, Limmroth C, Khalfaoui S, Schildgen V, et al. Acute human bocavirus infection in MDS patient, Cologne, Germany. J Clin Virol. 2015 in press.
93. Lin F, Zeng A, Yang N, Lin H, Yang E, Wang S, et al. Quantification of human bocavirus in lower respiratory tract infections in China. Infect Agent Cancer. 2007;2:3.
94. Medici MC, Tummofo L, Albonetti V, Abelli LA, Chezzi C, Calderaro A. Molecular detection and epidemiology of astrovirus, bocavirus, and sapovirus in Italian children admitted to hospital with acute gastroenteritis, 2008-2009. J Med Virol. 2012;84(4):643–50.
95. Meriluoto M, Hedman L, Tanner L, Simell V, Makinen M, Simell S, et al. Association of human bocavirus 1 infection with respiratory disease in childhood follow-up study. Finland Emerg Infect Dis. 2012;18(2):264–71.
96. Mitui MT, Tabib SM, Matsumoto T, Khanam W, Ahmed S, Mori D, et al. Detection of human bocavirus in the cerebrospinal fluid of children with encephalitis. Clin Infect Dis. 2012;54(7):964–7.
97. Monteny M, Niester HG, Moll HA, Berger MY. Human bocavirus in febrile children. The Netherlands Emerg Infect Dis. 2007;13(1):180–2.
98. Mori D, Ranawaka U, Yamada K, Rajindrajith S, Miya K, Perera HK, et al. Human bocavirus in patients with encephalitis, Sri Lanka, 2009-2010. Emerg Infect Dis. 2013;19(11):1859–62.
99. Niang MN, Diop OM, Sarr FD, Goudiaby D, Malou-Sompy H, Niaye K, et al. Viral etiology of respiratory infections in children under 5 years old living in tropical rural areas of Senegal: the EVIRA project. J Med Virol. 2010;82(5):866–72.
100. Obuchi M, Yagi S, Oguri A, Takizawa T, Kimura H, Sata T. Outbreak of human bocavirus 1 infection in young children in Toyama. Japan Jpn J Infect Dis. 2015;68(3):259–61.
101. Pierangeli A, Scagnolari C, Trombetti S, Grossi R, Battaglia M, Moretti C, et al. Human bocavirus infection in hospitalized children in Italy. Influenza Other Respir Viruses. 2008;2(5):175–9.
102. Pozo F, Garcia-Garcia ML, Calvo C, Cuesta I, Perez-Brena P, Casas I. High incidence of human bocavirus infection in children in Spain. J Clin Virol. 2007;40(3):224–8.
103. Qu XW, Duan ZJ, Qi ZY, Xie ZP, Gao HC, Liu WP, et al. Human bocavirus infection, People’s Republic of China. Emerg Infect Dis. 2007;13(1):165–8.
104. Redshaw N, Wood C, Rich F, Grimwood K, Kirman JR. Human bocavirus in infants. New Zealand Emerg Infect Dis. 2007;13(11):1797–9.
105. Santos N, Peret TC, Humphrey CD, Albuquerque MC, Silva RC, Benati FJ, et al. Human bocavirus species 2 and 3 in Brazil. J Clin Virol. 2010;48(2):127–30.
106. Smuts H, Hardie D. Human bocavirus in hospitalized children. South Africa Emerg Infect Dis. 2006;12(9):1457–8.
107. Soderlund-Venermo M, Lahtinen A, Jartti T, Hedman L, Kemppainen K, Lehtinen P, et al. Clinical assessment and improved diagnosis of bocavirus-induced wheezing in children, Finland. Emerg Infect Dis. 2009;15(9):1423–30.
108. Souza EL, Ramos JG, Prenca-Modena JL, Diniz A, Carvalho G, Ciufo I, et al. Human bocavirus in very young infants hospitalized with acute respiratory infection in Northeast Brazil. J Trop Pediatr. 2010;56(2):125–7.
109. Sung CC, Chi H, Chiu NC, Huang DT, Weng LC, Wang NY, et al. Viral etiology of acute lower respiratory tract infections in hospitalized young children in Northern Taiwan. J Microbiol Immunol Infect. 2011;44(3):184–90.
110. Tan BH, Lim EA, Seah SG, Loo LH, Tee NW, Lin RT, et al. The incidence of human bocavirus infection among children admitted to hospital in Singapore. J Med Virol. 2009;81(1):82–9.
111. Volz S, Schildgen O, Klinkenberg D, Ditt V, Muller A, Tillmann RL, et al. Prospective study of human Bocavirus (HBoV) infection in a pediatric university hospital in Germany 2005/2006. J Clin Virol. 2007;40(3):229–35.
112. Weissbrich B, Neske F, Schubert J, Tolland M, Blath K, Blessing K, et al. Frequent detection of bocavirus DNA in German children with respiratory tract infections. BMC Infect Dis. 2006;6:109.
113. Zhao LQ, Qian Y, Zhu RN, Deng J, Wang F, Dong HJ, et al. Seroprevalence of antibody against human bocavirus in Beijing, China. Zhonghua Er Ke Za Zhi. 2008;46(2):111–4.
114. Karalar L, Lindner J, Schimanski S, Kertai M, Segerer H, Modrow S. Prevalence and clinical aspects of human bocavirus infection in children. Clin Microbiol Infect. 2010;16(6):633–9.
115. Kantola K, Hedman L, Arthur J, Alibeto A, Delwart E, Jartti T, et al. Seroepidemiology of human bocaviruses 1-4. J Infect Dis. 2011;204(9):1403–12.
116. Li H, He M, Zeng P, Gao Z, Bian G, Yang C, et al. The genomic and seroprevalence of human bocavirus in healthy Chinese plasma donors and plasma derivatives. Transfusion. 2015;55(1):154–63.
117. Hamza H, Leifels M, Wilhelm M, Hamza IA. Relative abundance of human Bocaviruses in urban sewage in greater Cairo, Egypt. Food Environ Virol. 2017;9:304.

118. Chomnaitree T, Alvarez-Fernandez P, Jennings K, Trujillo R, Marom T, Loeffelholz MJ, et al. Symptomatic and asymptomatic respiratory viral infections in the first year of life: association with acute otitis media development. Clin Infect Dis. 2015;60(1):1–9.

119. Kaur J, Schildgen V, Tillmann R, Hardt A-L, Lüsebrink J, Windisch W, et al. Low copy number detection of HBoV DNA in BAL of asymptomatic adult patients. Future Virol. 2014;9(8):715–20.

120. Costa E, Rodriguez-Dominguez M, Clari MA, Gimenez E, Galan JC, Navarro D. Comparison of the performance of 2 commercial multiplex PCR platforms for detection of respiratory viruses in upper and lower tract respiratory specimens. Diagn Microbiol Infect Dis. 2015;82(1):40–3.

121. Chen KF, Blyn L, Rothman RE, Ramachandran P, Valsamakis A, Ecker D, et al. Reverse transcription polymerase chain reaction and electrospray ionization mass spectrometry for identifying acute viral upper respiratory tract infections. Diagn Microbiol Infect Dis. 2011;69(2):179–86.

122. Cotton M, Innes S, Jaspan H, Madide A, Rabie H. Management of upper respiratory tract infections in children. S Afr Fam Pract (2004). 2008;50(2):6–12.

123. Zeng SZ, Xiao NG, Zhong LL, Yu T, Zhang B, Duan ZJ. Clinical features of human metapneumovirus genotypes in children with acute lower respiratory tract infection in Changsha, China. J Med Virol. 2015.

124. Li L, Chen ZR, Yan YD, He LP, Xu HM, Shao XJ, et al. Detection of human bocavirus in nasopharyngeal aspirates versus in broncho-alveolar lavage fluids in children with lower respiratory tract infections. J Med Virol. 2015.

125. Ghietto LM, Camara A, Zhou Y, Pedranti M, Ferreyra S, Frey T, et al. High prevalence of human bocavirus 1 in infants with lower acute respiratory tract disease in Argentina, 2007-2009. Braz J Infect Dis. 2012;16(1):38–44.

126. Deng Y, Gu X, Zhao X, Luo J, Luo Z, Wang L, et al. High viral load of human bocavirus correlates with duration of wheezing in children with severe lower respiratory tract infection. PLoS One. 2012;7(3):e34353.

127. Arnott A, Vong S, Rith S, Naughtin M, Ly S, Guillard B, et al. Human bocavirus amongst all-ages population hospitalised with acute lower respiratory infections in Cambodia. Influenza Other Respir Viruses. 2012;7:201.

128. Pavia AT. Viral infections of the lower respiratory tract: old viruses, new viruses, and the role of diagnosis. Clin Infect Dis. 2011;52(Suppl 4):S284–9.

129. Zhang LL, Tang LY, Xie ZD, Tan XJ, Li CS, Cui AL, et al. Human bocavirus in children suffering from acute lower respiratory tract infection in Beijing Children’s hospital. Chin Med J. 2008;121(17):1607–10.

130. Schenk T, Huck B, Forster J, Berner R, Neumann-Haefelin D, Falcone V. Human bocavirus DNA detected by quantitative real-time PCR in two children hospitalized for lower respiratory tract infection. Eur J Clin Microbiol Infect Dis. 2007;26(2):147–9.

131. Kleines M, Scheithauer S, Rackowitz A, Ritter K, Hausler M. High prevalence of human bocavirus detected in young children with severe acute lower respiratory tract disease by use of a standard PCR protocol and a novel real-time PCR protocol. J Clin Microbiol. 2007;45(3):1032–4.

132. Freymuth F, Vabret A, Dina J, Petijean J, Gouarin S. Techniques used for the diagnostic of upper and lower respiratory tract viral infections. Rev Prat. 2007;57(17):1876–82.

133. Ma X, Endo R, Ishiguro N, Ebihara T, Ishiko H, Ariga T, et al. Detection of human bocavirus in Japanese children with lower respiratory tract infections. J Clin Microbiol. 2006;44(3):1132–4.

134. Liu WK, Chen DH, Liu Q, Liang HX, Yang ZF, Qin S, et al. Detection of human bocavirus from children and adults with acute respiratory tract illness in Guangzhou, southern China. BMC Infect Dis. 2011;11:345.
135. Midilli K, Yilmaz G, Turkoglu S, Iskanova B, Ergin S, Yarimcam F, et al. Detection of human bocavirus DNA by polymerase chain reaction in children and adults with acute respiratory tract infections. Mikrobiyol Bul. 2010;44(3):405–13.

136. Kupfer B, Vehreschild J, Cornely O, Kaiser R, Plum G, Viazov S, et al. Severe pneumonia and human bocavirus in adult. Emerg Infect Dis. 2006;12(10):1614–6.

137. Li X, Kantola K, Hedman L, Arku B, Hedman K, Soderlund-Venermo M. Original antigenic sin with human bocaviruses 1-4. J Gen Virol. 2015;96:3099.

138. Proenca-Modena JL, Paula FE, Buzatto GP, Carenzi LR, Saturno TH, Prates MC, et al. Hypertrophic adenoid is a major infection site of human bocavirus 1. J Clin Microbiol. 2014;52(8):3030–7.

139. Clement N, Battaglioli G, Jensen RL, Schneppe BC, Johnson PR, St George K, et al. Prevalence of human bocavirus in human tonsils and adenoids. Emerg Infect Dis. 2009;15(7):1149–50.

140. Wagner JC, Pyles RB, Miller AL, Nokso-Koivisto J, Loeffelholz MJ, Chonmaitree T. Determining persistence of Bocavirus DNA in the respiratory tract of children by pyrosequencing. Pediatr Infect Dis J. 2016;35(5):471–6.

141. Ergul AB, Altug U, Aydin K, Guven AS, Altuner TY. Acute necrotizing encephalopathy causing human bocavirus. Neuroradiol J. 2017; https://doi.org/10.1177/1971400916687586.

142. Khalfaoui S, Eichhorn V, Karagiannidis C, Bayh I, Brockmann M, Pieper M, et al. Lung infection by human Bocavirus induces the release of Profibrotic mediator cytokines in vivo and in vitro. PLoS One. 2016;11(1):e0147010.

143. Kumar A, Filippone C, Lahtinen A, Hedman L, Soderlund-Venermo M, Hedman K, et al. Comparison of Th-cell immunity against human bocavirus and parvovirus B19: proliferation and cytokine responses are similar in magnitude but more closely interrelated with human bocavirus. Scand J Immunol. 2011;73(2):135–40.

144. Chen H, Chen XZ, Waterboer T, Castro FA, Brenner H. Viral infections and colorectal cancer: a systematic review of epidemiological studies. Int J Cancer. 2015;137(1):12–24.

145. Schildgen V, Khalifaoui S, Schildgen O. Human Bocavirus: from common cold to cancer? Speculations on the importance of an episomal genomic form of human bocavirus. Rev Med Microbiol. 2014;25(4):113–8.

146. Schildgen V, Malecki M, Tillmann RL, Brockmann M, Schildgen O. The human Bocavirus is associated with some lung and colorectal cancers and persists in solid tumors. PLoS One. 2013;8(6):e68020.

147. Abdel-Moneim AS, El-Fol HA, Kamel MM, Soliman AS, Mahdi EA, El-Gammal AS, et al. Screening of human bocavirus in surgically excised cancer specimens. Arch Virol. 2016228:108

148. Gunel C, Kirdar S, Omurlu IK, Agdas F. Detection of the Epstein-Barr virus, human Bocavirus and novel KI and KU polyomaviruses in adenontonsillar tissues. Int J Pediatr Otorhinolaryngol. 2015;79(3):423–7.

149. Lu X, Gooding LR, Erdman DD. Human bocavirus in tonsillar lymphocytes. Emerg Infect Dis. 2008;14(8):1332–4.

150. Bagnato G, Harari S. Cellular interactions in the pathogenesis of interstitial lung diseases. Eur Respir Rev. 2012;21(125):102–14.

151. Keane MP. The role of chemokines and cytokines in lung fibrosis. Eur Respir Rev. 2008;17(109):151–6.

152. Gauldie J, Jordana M, Cox G. Cytokines and pulmonary fibrosis. Thorax. 1993;48(9):931–5.

153. Belperio JA, Dy M, Murray L, Burdick MD, Xue YY, Strieter RM, et al. The role of the Th2 CC chemokine ligand CCL17 in pulmonary fibrosis. J Immunol. 2004;173(7):4692–8.

154. Kishi M, Miyazaki Y, Jinta T, Furusawa H, Ohtani Y, Inase N, et al. Pathogenesis of cBFL in common with IPF? Correlation of IP-10/TARC ratio with histological patterns. Thorax. 2008;63(9):810–6.

155. Luo H, Zhang Z, Zheng Z, Ke X, Zhang X, Li Q, et al. Human bocavirus VP2 upregulates IFN-beta pathway by inhibiting ring finger protein 125-mediated ubiquitination of retinoic acid-inducible gene-I. J Immunol. 2013;191(2):660–9.
156. Zhang Z, Zheng Z, Luo H, Meng J, Li H, Li Q, et al. Human bocavirus NP1 inhibits IFN-beta production by blocking association of IFN regulatory factor 3 with IFNB promoter. J Immunol. 2012;189(3):1144–53.
157. Liu Q, Zhang Z, Zheng Z, Zheng C, Liu Y, Hu Q, et al. Human Bocavirus NS1 and NS1-70 proteins inhibit TNF-alpha-mediated activation of NF-kappaB by targeting p65. Sci Rep. 2016;6:28481.
158. Martin ET, Fairchok MP, Stednick ZJ, Kuypers J, Englund JA. Epidemiology of multiple respiratory viruses in childcare attendees. J Infect Dis. 2013;207(6):982–9.
159. Martin ET, Kuypers J, McRoberts JP, Englund JA, Zerr DM. Human Bocavirus 1 primary infection and shedding in infants. J Infect Dis. 2015;212(4):516–24.
160. Balada-Llasat JM, LaRue H, Kelly C, Rigali L, Pancholi P. Evaluation of commercial ResPlex II v2.0, MultiCode-PLx, and xTAG respiratory viral panels for the diagnosis of respiratory viral infections in adults. J Clin Virol. 2011;50(1):42–5.
161. Pham NT, Trinh QD, Chan-It W, Khamrin P, Shimizu H, Okitsu S, et al. A novel RT-multiplex PCR for detection of Aichi virus, human parechovirus, enteroviruses, and human bocavirus among infants and children with acute gastroenteritis. J Virol Methods. 2010;169(1):193–7.
162. Spyridaki IS, Christodoulou I, de Beer L, Hovland V, Kurowski M, Olszewska-Ziaber A, et al. Comparison of four nasal sampling methods for the detection of viral pathogens by RT-PCR-A GA(2)LEN project. J Virol Methods. 2009;156(1–2):102–6.
163. Arden KE, McErlean P, Nissen MD, Sloots TP, Mackay IM. Frequent detection of human rhinoviruses, paramyxoviruses, and bocavirus during acute respiratory tract infections. J Med Virol. 2006;78(9):1232–40.
164. Loefelholz MJ, Pong DL, Pyles RB, Xiong Y, Miller AL, Button KK, et al. Comparison of the FilmArray respiratory panel and Prodesse real-time PCR assays for detection of respiratory pathogens. J Clin Microbiol. 2011;49(12):4083–8.
165. Nawaz S, Allen DJ, Aladin F, Gallimore C, Iturriza-Gomara M. Human bocaviruses are not significantly associated with gastroenteritis: results of retesting archive DNA from a case control study in the UK. PLoS One. 2012;7(7):e41346.
166. Martin ET, Taylor J, Kuypers J, Magaret A, Wald A, Zerr D, et al. Detection of bocavirus in saliva of children with and without respiratory illness. J Clin Microbiol. 2009;47(12):4131–2.
167. Williams JV. Deja vu all over again: Koch’s postulates and virology in the 21st century. J Infect Dis. 2010;201(11):1611–4.
168. von Linstow ML, Hogh M, Hogh B. Clinical and epidemiologic characteristics of human bocavirus in Danish infants: results from a prospective birth cohort study. Pediatr Infect Dis J. 2008;27(10):897–902.
169. Garcia-Garcia ML, Calvo C, Pozo F, Perez-Brena P, Quevedo S, Bracamonte T, et al. Human bocavirus detection in nasopharyngeal aspirates of children without clinical symptoms of respiratory infection. Pediatr Infect Dis J. 2008;27(4):358–60.
170. Ursic T, Krivec U, Kalan G, Petroveck F. Fatal human bocavirus infection in an 18-month-old child with chronic lung disease of prematurity. Pediatr Infect Dis J. 2015;34(1):111–2.
171. Ghiotto LM, Majul D, Ferreyra Soaje P, Baumeister E, Avaro M, Insfran C, et al. Comorbidity and high viral load linked to clinical presentation of respiratory human bocavirus infection. Arch Virol. 2015;160(1):117–27.
172. Campbell AP, Guthrie KA, Englund JA, Farney RM, Minerich EL, Kuypers J, et al. Clinical outcomes associated with respiratory virus detection before allogeneic hematopoietic stem cell transplant. Clin Infect Dis. 2015;61(2):192–202.
173. Akturk H, Sik G, Salman N, Sutcu M, Tatli B, Ciblak MA, et al. Atypical presentation of human bocavirus: severe respiratory tract infection complicated with encephalopathy. J Med Virol. 2015;87(11):1831–8.
174. Kim JS, Lim CS, Kim YK, Lee KN, Lee CK. Human bocavirus in patients with respiratory tract infection. Korean J Lab Med. 2011;31(3):179–84.
175. Haidopoulou K, Goutaki M, Damianidou L, Eboriadou M, Antoniadis A, Papa A. Human bocavirus infections in hospitalized Greek children. Arch Med Sci. 2010;6(1):100–3.
The Role of the Human Bocavirus (HBoV) in Respiratory Infections

176. Beder LB, Hotomi M, Ogami M, Yamauchi K, Shimada J, Billal DS, et al. Clinical and microbiological impact of human bocavirus on children with acute otitis media. Eur J Pediatr. 2009;168(11):1365–72.

177. Deng X, Li Y, Qiu J. Human bocavirus 1 infects commercially available primary human airway epithelium cultures productively. J Virol Methods. 2014;195:112–9.

178. Lehtoranta L, Soderlund-Venermo M, Nokso-Koivisto J, Toivola H, Blomgren K, Hatakka K, et al. Human bocavirus in the nasopharynx of otitis-prone children. Int J Pediatr Otorhinolaryngol. 2012;76(2):206–11.

179. Schenk T, Maier B, Hufnagel M, Strahm B, Kontny U, Neumann-Haefelin D, et al. Persistence of human bocavirus DNA in immunocompromised children. Pediatr Infect Dis J. 2011;30(1):82–4.

180. Martin ET, Fairchok MP, Kuyers J, Magaret A, Zerr DM, Wald A, et al. Frequent and prolonged shedding of bocavirus in young children attending daycare. J Infect Dis. 2010;201(11):1625–32.

181. Storch GA. Plethora of respiratory viruses and respiratory virus data. Clin Infect Dis. 2015;61:1225.

182. Babady NE, Mead P, Stiles J, Brennan C, Li H, Shuptar S, et al. Comparison of the Luminex xTAG RVP fast assay and the Idaho technology FilmArray RP assay for detection of respiratory viruses in pediatric patients at a Cancer hospital. J Clin Microbiol. 2012;50(7):2282–8.

183. Nascimento-Carvalho CM, Cardoso MR, Meriluoto M, Kempainen K, Kantola K, Ruuskanen O, et al. Human bocavirus infection diagnosed serologically among children admitted to hospital with community-acquired pneumonia in a tropical region. J Med Virol. 2012;84(2):253–8.

184. Don M, Soderlund-Venermo M, Hedman K, Ruuskanen O, Allander T, Korppi M. Don't forget serum in the diagnosis of human bocavirus infection. J Infect Dis. 2011;203(7):1031–2. author reply 2-3.

185. Hedman L, Soderlund-Venermo M, Jartti T, Ruuskanen O, Hedman K. Dating of human bocavirus infection with protein-denaturing IgG-avidity assays-secondary immune activations are ubiquitous in immunocompetent adults. J Clin Virol. 2010;48(1):44–8.

186. Don M, Soderlund-Venermo M, Valent F, Lahtinen A, Hedman L, Canciani M, et al. Serologically verified human bocavirus pneumonia in children. Pediatr Pulmonol. 2010;45(2):120–6.

187. Kantola K, Hedman L, Allander T, Jartti T, Lehtinen P, Ruuskanen O, et al. Serodiagnosis of human bocavirus infection. Clin Infect Dis. 2008;46(4):540–6.

188. Christensen A, Dollner H, Skanke LH, Kroksdast S, Moe N, Nordbo SA. Detection of spliced mRNA from human bocavirus 1 in clinical samples from children with respiratory tract infections. Emerg Infect Dis. 2013;19(4):574–80.

189. Bruning AH, Susi P, Toivola H, Christensen A, Soderlund-Venermo M, Hedman K, et al. Detection and monitoring of human bocavirus 1 infection by a new rapid antigen test. New Microbes New Infec. 2016;11:17–9.

190. Tamosiunas PL, Petraityte-Burneikiene R, Bulavaite A, Marcinkeviciute K, Simutis K, Lasickiene R, et al. Yeast-generated virus-like particles as antigens for detection of human bocavirus 1-4 specific antibodies in human serum. Appl Microbiol Biotechnol. 2016;100(11):4935–46.

191. Kailasan S, Garrison J, Ilyas M, Chipman P, McKenna R, Kantola K, et al. Mapping antigenic epitopes on the human Bocavirus capsid. J Virol. 2016;90(9):4670–80.